Hansa Biopharma reports robust Q4 with SEK 50m revenue By Investing.com
© Reuters.
LUND, Sweden - Hansa Biopharma, a leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced a business update for the fourth quarter of 2023. The company expects to report SEK 50 million in…
